Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Japan Officially Eases Trial Recruitment Rules; Industry Welcomes Move
Japan’s Ministry of Health, Labor and Welfare (MHLW) has issued a notification formalizing its position that information provided to recruit participants for clinical trials will not be considered “advertising” under the Pharmaceuticals and Medical Devices (PMD) Act. The March 30…
To read the full story
Related Article
- MHLW Says Trial Recruitment Info Not Deemed Advertising Under PMD Act
March 27, 2026
- MHLW Plans to Ease Clinical Trial Ad Rules, Eyes Notification by March-End
July 24, 2025
- Regulatory Reform Panel Calls for Review of Clinical Trial Ad Rules
May 30, 2025
- Clinical Trial Matching Websites Do Not Violate Ad Regulations in PMD Act: MHLW
April 10, 2025
- Revise Regulations of Clinical Trial Info in PMD Act: Patient Advocate to Diet
April 9, 2025
- Govt’s Regulatory Reform Panel Discusses Access to Clinical Trial Information
March 7, 2025
REGULATORY
- MHLW Study Group Proposes Six Options to Put Japan’s Patent Linkage System into Law
July 9, 2026
- Chuikyo Kicks Off Debate on FY2027 Off-Year Drug Price Revision
July 9, 2026
- Boehringer’s Big-Seller Hopeful Jascayd Set for Listing, Haihe’s Haizexin Too
July 9, 2026
- Chuikyo OKs NHI Listing for Ferring’s Adstiladrin, Ishin’s Allostem Sheet
July 9, 2026
- JPA’s Watanabe Joins Chuikyo as Healthcare Provider Rep
July 9, 2026
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…